Audí Laura, Esteban Cristina, Carrascosa Antonio, Espadero Rosa, Pérez-Arroyo Annalisa, Arjona Rosa, Clemente María, Wollmann Hartmut, Fryklund Linda, Parodi Luis A
Department of Pediatrics, Hospital Vall D'Hebron, Autonmous University, Barcelona, Spain.
J Clin Endocrinol Metab. 2006 Dec;91(12):5038-43. doi: 10.1210/jc.2006-0828. Epub 2006 Sep 26.
A polymorphism in the human GH receptor gene (d3/fl-GHR) resulting in genomic deletion of exon 3 has been associated with the degree of height increase in response to GH therapy.
The objective of the study was to evaluate the frequencies of d3/fl-GHR polymorphism genotypes in control and short small-for-gestational-age (SGA) populations.
An adult control population with heights normally distributed (ACPNH) between -2 and +2 sd score (SDS) and a short non-GH-deficient SGA child population were selected.
Thirty Spanish hospitals participated in the selection of the short non-GH-deficient SGA children in the setting of a controlled, randomized trial, and one of these hospitals selected the ACPNH. CONTROLS AND PATIENTS: Two hundred eighty-nine adult subjects of both sexes constituted the ACPNH and 247 children and adolescents of both sexes the short SGA patients.
Heights and weights were recorded in the ACPNH, and auxologic and biochemical data were recorded at each hospital for the SGA patients; d3/fl-GHR genotypes were determined and data analyzed in a single hospital.
In short SGA patients, d3/fl-GHR genotype frequencies were significantly different from those in ACPNH, with a higher frequency of fl/fl genotype (P < 0.0001). In ACPNH, a trend toward diminished d3/d3 genotype frequency was observed in the shortest height group (height <or=-1 SDS and >or=-2 SDS, n = 60).
Our data showed significant differences in the frequency distribution of the d3/fl-GHR genotypes between a normally distributed adult height population and short SGA children, with the biologically less active fl/fl genotype being almost twice as frequent in SGA patients. These data suggest that the d3/fl-GHR polymorphism might be considered among the factors that contribute to the phenotypic expression of growth.
人类生长激素受体基因(d3/fl-GHR)中的一种多态性导致外显子3的基因组缺失,这与生长激素治疗后的身高增长程度有关。
本研究的目的是评估对照人群和小于胎龄儿(SGA)矮小人群中d3/fl-GHR多态性基因型的频率。
选择身高在-2至+2标准差评分(SDS)之间呈正态分布的成年对照人群(ACPNH)和矮小的非生长激素缺乏的SGA儿童人群。
30家西班牙医院参与了一项对照随机试验中矮小的非生长激素缺乏的SGA儿童的选择,其中一家医院选择了ACPNH。对照与患者:289名成年男女构成ACPNH,247名男女儿童和青少年为矮小SGA患者。
记录ACPNH的身高和体重,各医院记录SGA患者的体格学和生化数据;在一家医院测定d3/fl-GHR基因型并进行数据分析。
在矮小SGA患者中,d3/fl-GHR基因型频率与ACPNH中的频率显著不同,fl/fl基因型频率更高(P<0.0001)。在ACPNH中,在最矮身高组(身高≤-1 SDS且≥-2 SDS,n = 60)中观察到d3/d3基因型频率有降低的趋势。
我们的数据显示,正常分布的成年身高人群与矮小SGA儿童之间d3/fl-GHR基因型的频率分布存在显著差异,生物学活性较低的fl/fl基因型在SGA患者中的频率几乎是其两倍。这些数据表明d3/fl-GHR多态性可能是影响生长表型表达的因素之一。